Febrile neutropenia: significance of elaborated screening for respiratory viruses, and the comparison of different sampling methods, in neutropenic patients with hematological malignancies

Table 2 PCR results in relation to patient characteristics

	Phase A	Phase B	Phase C
	N = 71	N = 46	N = 42
Viral positivity (percentage)	10/71 (14%)	6 (13%)	8 (19%)
Viral positivity in persons:
with URTS	1/15 (7%)	1/6 (16%)	1/9 (11%)
with LRTS	0	0	1/1 (100%)
without RTS	9/56 (16%)	5/40 (13%)	6/32 (19%)
Viral positivity in persons:
with suspected imagery^a	-	-	1/10⁹ (10%)
without suspected imagery^a	-	-	4/22⁹ (18%)
Nasal swab Positive (%)	6/57 (11%)	5/35 (14%)	5/25 (20%)
Pharyngeal swab Positive (%)	2/51 (4%)	2/33 (6%)	2/22 (9%)
Throat gurgle positive (%)	5/71 (7%)	4/42 (10%)	5/35(14%)
Frequencies of detect viral species:
RV	4 (6%)	1 (4%)	3 (7%)
RSV	1 (1%)	1(4%)	0
hMPV	0	0	1 (2%)
hBoV	2 (3%)	0	2 (4%)
PeV	1	0	0
AdV	1	0	1 (2%)
hCoV	1	2 (8%)	1 (2%)
PIV2	0	2	0
PIV3	0	1 (4%)	0

Phase A; Baseline population at onset of chemotherapy, notice that ten patients could not be sampled before the start of chemotherapy (N = 71), Phase B; Patients with deep neutropenia, without fever, Phase C; Prospective patients with deep neutropenia and fever. URTS upper respiratory tract symptoms, LRTS lower respiratory tract symptoms, RTS respiratory tract symptoms, RV rhinovirus, RSV respiratory syncytial virus, hMPV human metapneumovirus, HBoV human bocavirus, PeV parechovirus, AdV adenovirus, hCoV corona virus, PIV 2&3 para-influenza virus 1,2,3,4. CP-value crossing point value, IQR inter quartile range.
^a x-ray or CT-scan of the thorax.
^b The following viuses were not detected: Inf A/B; influenza viruses A and B, EV; enterovirus, para-influenza virus 1&4.

ISSN: 1743-422X